Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870974 · ClinicalTrials.gov registry record · Phase 1
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00870974 is a Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 48 participants.
The verdict
NCT00870974, a Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum Disorder(ASD), Alzheimer's Disease(AD), and subjects with mild cognitive impairment (MCI). The goal of this study is to assess \[18F\]F-PEB positron emission tomography (PET) imaging as a tool to detect mGluR5 density in the brain of PD, HD, FXS ASD, AD, and MCI research participants and similarly aged healthy subjects.
Interventions
- DRUG [18F]FPEB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870974
The ClinicalTrials.gov registry entry for NCT00870974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]FPEB is the first listed.
NCT00870974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00870974 about?
NCT00870974 is a clinical study titled "A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions". Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum Disorder(ASD), Alzheimer's Disease(A...
What is the current status of trial NCT00870974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2009-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00870974?
The interventions under investigation include: [18F]FPEB (DRUG).
Who is sponsoring clinical trial NCT00870974?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.